Thursday, 12 November 2026European Markets
Source trace. Via News points to the documents behind its reporting and shows what we drew from each — so you can check any claim. How we source
News articleYahoo Finance· November 15, 2025

Europe Gauges Fallout From Trump’s Year of Trade Chaos

View original at finance.yahoo.com
Europe Gauges Fallout From Trump’s Year of Trade Chaos Bound aluminum plates ahead of shipping at an aluminium smelter near Dunkirk, France…
Opening lines of the source · Yahoo Finance · short snapshot — read the full document at the original

What we drew from this source

The claims Via News extracted from this document. We point to the source; we don't replace it.

  • Still-elevated uncertainty, higher effective tariffs, a stronger euro and increased global competition are expected to hold back growth

    80% confidence
  • The European Commission is likely to raise the 2025 GDP estimate this time around

    80% confidence
  • Uncertainty is shaving about 0.5 percentage point off France's expansion, with domestic political and budget turbulence accounting for at least 0.2 point of that

    80% confidence
  • The economy may experience another period of soft business investment and weak external demand as a result of elevated uncertainty and fewer purchases from the other side of the Atlantic

    80% confidence
  • The European Central Bank anticipated 1% growth for 2026 in its September forecasting round

    80% confidence
  • Bank Indonesia Governor Perry Warjiyo likely to signal room for further cuts in the coming year

    80% confidence
  • The European Commission earlier predicted a 0.9% increase for gross domestic product in the euro area for 2025

    80% confidence
  • We forecast euro-area GDP growth to remain below trend in the final quarter of 2025 at 0.1%

    80% confidence
  • Rodriguez Ceja sees a quarter-point cut to 7% next month as highly likely

    80% confidence
  • Germany's Council of Economic Experts has lowered its outlook for expansion in 2026 to below 1%

    80% confidence

Cited in these Via News reports

What we know · the intelligence behind this page
Live from the substrate
What we're seeing
Biotech Catalyst Wave: Late-2026 Clinical Readouts, PDUFA Dates and Capital Restructuring
A dense cluster of Q4 2026 to Q1 2027 clinical and regulatory catalysts spans hepatitis delta (Vir's ECLIPSE/SOLSTICE), hypertension and sleep apnea (Mineralys' lorundrostat, PDUFA 2026-12-22), severe hypertriglyceridemia (plozasiran), oncology (ivonescimab BLA, PDUFA 2026-11-14) and gene therapy (Krystal). Positive data flow from AASLD and AHA presentations is offset by cost-cutting guidance, milestones slipping into 2027, and a delisting process that signals capital-market stress for some issuers. Near-term value hinges on binary FDA decisions and Phase 3 topline readouts in Q1 2027.
Our read on the data ›
Signals we're tracking
EPKINLY Regulatory-Clinical Success Cascade
High probability of expanded label indications, additional combination approvals, and competitive positioning strength in follicular lymphoma market. Predicts positive commercial uptake and potential accelerated review for related indications.
Patterns we're watching ›
Where sources disagree
Ford Motor Company
Both facts give cash for Ford Motor Company at the same point in time (2025-12-31; FY 2025 year-end and Q4 2025 year-end are the same date). Both are labelled USD, but the values are 23,356,000,000 and 23.356, which cannot both be true in USD. The two numbers agree once the second is read as billions (23.356 bn = 23,356,000,000), so the economic content is consistent and the conflict is a unit/scale error in the Q4 2025 record. The period is not the reason for the conflict: a Q4 and an FY figure at the same year-end date should match.
We flag conflicts openly ›
Recently verified
✓ Checked against the original source
4,995
facts traced to their source — and we flag the ones that don't hold up.
101 entities tracked4,995 facts checked against source5,565 source documents archived
Query this data → isubstrate.com